Silexion Therapeutics Corp. Files 8-K

Ticker: SLXNW · Form: 8-K · Filed: Jan 15, 2025 · CIK: 2022416

Sentiment: neutral

Topics: corporate-action, name-change

Related Tickers: SLXN

TL;DR

Silexion Therapeutics (fka Biomotion Sciences) filed an 8-K on Jan 15, 2025.

AI Summary

Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on January 15, 2025, reporting on its corporate actions. The company, incorporated in the Cayman Islands and headquartered in Ramat-Gan, Israel, is involved in the biological products sector. This filing indicates a name change from Biomotion Sciences to Silexion Therapeutics Corp. effective May 6, 2024.

Why It Matters

This filing formally documents the corporate name change of Silexion Therapeutics Corp., which was previously known as Biomotion Sciences, providing clarity for investors and stakeholders.

Risk Assessment

Risk Level: low — The filing is a routine corporate disclosure and does not contain information that inherently increases risk.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report current information about Silexion Therapeutics Corp., including its corporate status and a previous name change.

When was Silexion Therapeutics Corp. previously known?

Silexion Therapeutics Corp. was previously known as Biomotion Sciences.

On what date did the company's name change occur?

The date of the name change from Biomotion Sciences to Silexion Therapeutics Corp. was May 6, 2024.

Where are Silexion Therapeutics Corp.'s principal executive offices located?

Silexion Therapeutics Corp.'s principal executive offices are located at 12 Abba Hillel Road, Ramat-Gan, Israel.

What is the SIC code for Silexion Therapeutics Corp.?

The Standard Industrial Classification (SIC) code for Silexion Therapeutics Corp. is 2836, which corresponds to Biological Products (No Diagnostic Substances).

Filing Stats: 526 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2025-01-15 06:02:06

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 15, 2025, Silexion Therapeutics Corp presented publicly an updated corporate presentation. A copy of the presentation is furnished with this Current Report on Form 8-K (this " Form 8-K ") as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 7.01, including the information in the corporate presentation that is being furnished pursuant to this Item 7.01 of Form 8-K, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Furthermore, the information in Item 7.01 of this Form 8-K, including the information in the corporate presentation, shall not be deemed to be incorporated by reference in the filings of the registrant under the Securities Act of 1933, as amended.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits 99.1 Corporate Presentation 104 Cover Page Interactive Data File (formatted in Inline XBRL) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SILEXION THERAPEUTICS CORP Date: January 15, 2025 /s/ Ilan Hadar Name: Ilan Hadar Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing